Austrian court upholds Novogen patent for isoflavone product

By Lisa Kerner

Charlotte, N.C., June 15 - The Vienna Commercial Court has found that Novogen's isoflavone invention and patent is novel and inventive, according to a company news release.

In addition, the court found APOtrend's menopause product, Vitalady, infringed Novogen's patent and the provisional injunction against Vitalady has been upheld.

As a result, APOtrend must retract all infringing Vitalady products from retail, wholesale and other sales channels.

"The Vienna Commercial Court findings are a reflection of similar patent success Novogen has experienced in Canada and the United States," Novogen representative Renate Moser said in the release.

"Novogen will continue to protect and enforce its intellectual property rights around the world for the benefit of users of nutritional supplements."

Novogen is an Australian-based biotechnology developing drugs derived from its phenolic technology platform.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.